Evidence map›Paper›PMID 38889704›Full record

ArticleDementia and geriatric cognitive disorders2024

Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers.

Kasia Gustaw Rothenberg, Lynn Bekris, James B Leverenz, Jenny Wu, Jonathan Lee, Volodymyr Statsevych, Paul Ruggieri, Stephen E Jones

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dementia and geriatric cognitive disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kasia Gustaw RothenbergLou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Lynn BekrisGenomic Medicine Institute Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
James B LeverenzLou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Jenny WuDepartment of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.
Jonathan LeeDepartment of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.
Volodymyr StatsevychDepartment of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.
Paul RuggieriDepartment of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.
Stephen E JonesDepartment of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

Translational and Therapeutics CoreP30AG072959 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Mark J Lowe · 2021 to 2026
$23.9M
Dementia with Lewy Bodies Consortium - Supplement for ASL sequenceU01NS100610 · NINDS · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI DOUGLAS R GALASKO, JAMES Bruce LEVERENZ · 2016 to 2026
$15.6M
NIA NIH HHS P30 AG072959NINDS NIH HHS U01 NS100610
6 · The paper itself

Abstract

introductionCerebral amyloid angiopathy (CAA) is characterized by amyloid β (Aβ) deposition in brain vessels, leading to hemorrhagic phenomena and cognitive impairment. Magnetic resonance imaging (MRI)-based criteria allow a diagnosis of probable CAA in vivo, but such a diagnosis cannot predict the eventual development of CAA.

methodsWe conducted a retrospective cohort study of 464 patients with cognitive disorders whose data were included in a brain health biobank. De-identified parameters including sex, age, cognitive score, APOE status, and cerebrospinal fluid (CSF) levels of Aβ 1-40, Aβ 1-42, phosphorylated tau, and total tau were assessed in those with and without CAA. Odds ratios (ORs) and 95% confidence intervals (CIs) were determined.

resultsCAA was present in 53 of 464 (11.5%) patients. P-tau level was significantly higher in those with CAA (115 vs. 84.3 pg/mL p = 0.038). In univariate analyses, the risk of developing CAA was higher with increased age (OR, 1.036; 95% CI: 1.008, 1.064; p = 0.011) and decreased CSF level of Aβ 1-40 (OR, 0.685; 95% CI: 0.534, 0.878; p = 0.003). In multivariate analyses, the risk of CAA remained higher with a decreased CSF level of Aβ 1-40 (OR, 0.681; 95% CI: 0.531, 0.874; p = 0.003).

conclusionThese findings suggest that Aβ 1-40 levels in the CSF might be a useful molecular biomarker of CAA in patients with dementia.

Indexed as

Amyloid beta-PeptidesBiomarkersCerebral Amyloid AngiopathyCognitive Dysfunctiontau ProteinsAgedAged, 80 and overFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPeptide FragmentsRetrospective StudiesAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau ProteinsAPOECerebral amyloid angiopathyDementiaMagnetic resonance imaging

Identifiers

PMID38889704
PMCPMC11446477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.